ClinicalTrials.gg
CompletedNCT03450980Updated Jul 14, 2025Results posted

Mobile Medical Application for Cost-effective Strabismus Screening

An observational study in Strabismus, sponsored by Massachusetts Eye and Ear Infirmary. Completed at 1 site in United States. Open to participants aged 18 Years to 88 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Massachusetts Eye and Ear Infirmary · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
91
Ages
18 Years to 88 Years
Sex
All
01

Study summary

Develop and evaluate a new smartphone based app to screen for and measure eye misalignment (strabismus). The investigators will validate the app against simulated strabismus of known magnitude and common clinical tests. They will evaluate the app as a screening tool in high risk populations, to determine the sensitivity and specificity. They hypothesize that the app can measure to within 2 units (prism diopters) of the ground truth, and that it will be correlated with gold standard tests.

Read the detailed description

The goal of the proposed project is the development and evaluation of a novel mobile medical application for the detection and monitoring of strabismus (eye misalignment). The image analysis technology necessary to measure strabismus using the corneal reflection technique (Photographic Hirschberg Test) has been available for many decades, however it has never been deployed using a smart phone. A smart phone platform will eliminate barriers of cost (since the hardware is maintained and updated by the smart phone industry), leading to rapid wide spread application and allowing the technology to finally reach its potential level of impact for children's eye care in the detection and management of strabismus. Strabismus causes visual confusion and double vision which ultimately results in the brain suppressing vision from the deviated eye. In children this results in under-development (amblyopia) with permanent vision loss in the deviated eye if not detected and treated at a young age. Strabismus in children is also associated with coordination problems such as postural instability and severe social disadvantages. Strabismus develops in an estimated 3-8% of children in the U.S. The prototype smart phone app (Referred to here as the Mobile Eye Alignment App - MEAA), uses photographic analysis of the corneal reflection (Purkinjie image) generated by the smart phone camera flash. The corneal reflection method uses the displacement of the reflection from the center of the pupil in the deviated eye to calculate the amount of eye misalignment. This measurement technique will be deployed for the proposed project using the hardware of the iPhone, a popular phone with an iOS operating system. Preliminary results suggest the app can measure differences in eye alignment of 1.6° (2.8 prism diopters). If successfully developed, the app has potential to be utilized to advance pediatric strabismus research by facilitating and reducing the cost of collecting enormous amounts of data from the general population and under-served or remote populations for epidemiological studies, and allowing researchers to capture eye alignment data much more frequently than is currently possible. Such a tool could better delineate the natural history of strabismus and perhaps help determine its causes. While devices are available which could make these measurements, the costs are prohibitively high (>$3,000 ea.) and will not reach the widespread availability of smart phones. Clinical goals for the app are to provide eye doctors with an objective measurement tool in the exam room, allow daily monitoring of treatment effects, and eventually to be used as a screening tool by school nurses, pediatricians, and parents. The barriers to market success of stand-alone devices is not the accuracy sensitivity or specificity of photographic analysis technique which has been reported with sensitivity from 53% to near 90% and specificity ranging from 76% to 94% for strabismus detection. Impact of strabismus screening for the young - Early detection for strabismus in young children, especially during the critical period up to 2 years of age, is important to ensure that treatment is administered as soon as possible. The success of amblyopia treatment depends on several factors, but principally on the age of onset and the age at which the treatment is initiated. Therapy for amblyopia is maximally effective if started before age 3 and can be initiated as early as 8 months, underscoring the critical need for early and widespread access to strabismus screening. Indeed, countries with long-standing early vision screening programs have reported significantly reduced rates of amblyopia. Access to strabismus screening is also important for older, school age children (age 7-17) suffering from amblyopia, for whom treatment can lead to significant improvements in visual acuity ranging from 20%-70% of patients, depending on their age bracket.

Aims

AIM 1:

Develop and test key functionality of the strabismus app by comparing measurements with successive versions of the prototype app to known angles of eye deviation (non-strabismic volunteers will gaze at off axis targets of known eccentricity).

AIM 2:

Evaluate the strabismus app accuracy and feasibility in participants with strabismus tested with both the app and clinical methods and analyzed for levels of agreement.

Primary Hypothesis: For strabismus ranging from 1 to 30 prism diopters (target range), the optimized version of the app will provide measurements which are highly correlated with the ground truth (simulated strabismus) or clinical tests of eye alignment.

02

Conditions studied

  • Strabismus

Keywords

  • Double Vision, Amblyopia
03

In context

Strabismus

142 studies on the registry are indexed under Strabismus; 31 are open to participants now.

This study's enrollment of 91 is close to the median of 96 across 54 observational studies indexed under Strabismus.

Browse Strabismus studies →

Lead sponsor

Massachusetts Eye and Ear Infirmary is the lead sponsor of 100 studies on the registry; 23 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Normal vision participants with simulated strabismus and participants with strabismus.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ground Truth Aim Study:

  • Age 18 to 88 years
  • Normal or corrected to normal vision

Clinical Aim Study:

  • Ages 18 to 88
  • Strabismus
  • Able to keep looking at a visual target for 30-60 seconds

Exclusion criteria

Exclusion Criteria:

Ground Truth Aim Study:

  • Age less than 18 years or greater than 88.

Clinical Study:

  • Age less than 18 or greater than 88
  • Inability to keep looking at a visual target for 30-60 seconds
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
91 participants (actual)
Patient registry
No

Groups and cohorts

  • Strabismus

    Participants with strabismus had measurement with the app and compared to the cover test with prism neutralization (gold standard) or eye turning to know eccentricity.

06

What researchers measure

Primary outcomes

  1. Comparison of App-measured Eye Deviation Angles to Gold Standard

    Linear regression analysis was used to compare the app measurements of strabismus angle to ground truth and gold standard measures. The outcome measure is the difference between the two methods, in terms of least square mean (LSM).

    Time frame: 15 minutes

07

Results

Posted Jul 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneParticipants With Varied Ocular Deviation
Started91
Completed91
Not completed0

Outcome measures

PrimaryComparison of App-measured Eye Deviation Angles to Gold Standard

Linear regression analysis was used to compare the app measurements of strabismus angle to ground truth and gold standard measures. The outcome measure is the difference between the two methods, in terms of least square mean (LSM).

Time frame:
15 minutes
Reported as:
Least squares mean · prism diopter
Comparison of App-measured Eye Deviation Angles to Gold Standard
prism diopterParticipants With Ocular Deviation
Comparison of App-measured Eye Deviation Angles to Gold Standard3.3 ± 4.2

Adverse events

Collected over Monitored during one study visit, which was typically one hour.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants With Ocular Deviation0/91 (0%)0/91 (0%)0/91 (0%)

Baseline characteristics

Normal vision participants with simulated strabismus and participants with strabismus

Age, Categorical
Age, Categorical(Participants)Participants With Varied Ocular Deviation
<=18 years36
Between 18 and 65 years55
>=65 years0
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Participants With Varied Ocular Deviation
Undisclosed25
Male36
Female30
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Participants With Varied Ocular Deviation
08

Study locations

1 site
  • Ophthalmology of Clinical Research Office, Mass Eye and Ear
    Boston, Massachusetts 021141, United States
09

References and documents

Publications

  • Brodie SE. Photographic calibration of the Hirschberg test. Invest Ophthalmol Vis Sci. 1987 Apr;28(4):736-42. PubMed 3557878 ↗
  • Rowe, F.J., Clinical Orthoptics. 3rd ed. 2012: Wiley and Sons. 486.
  • Taylor K, Elliott S. Interventions for strabismic amblyopia. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD006461. doi: 10.1002/14651858.CD006461.pub3. PubMed 21833955 ↗
  • Cotter SA, Tarczy-Hornoch K, Song E, Lin J, Borchert M, Azen SP, Varma R; Multi-Ethnic Pediatric Eye Disease Study Group. Fixation preference and visual acuity testing in a population-based cohort of preschool children with amblyopia risk factors. Ophthalmology. 2009 Jan;116(1):145-53. doi: 10.1016/j.ophtha.2008.08.031. Epub 2008 Oct 29. PubMed 18962921 ↗
  • Loudon SE, Rook CA, Nassif DS, Piskun NV, Hunter DG. Rapid, high-accuracy detection of strabismus and amblyopia using the pediatric vision scanner. Invest Ophthalmol Vis Sci. 2011 Jul 7;52(8):5043-8. doi: 10.1167/iovs.11-7503. PubMed 21642624 ↗
  • Barnard, S. and E. Johnson, Detecting strabismus. Optician, 2013.
  • Klaver P, Marcar V, Martin E. Neurodevelopment of the visual system in typically developing children. Prog Brain Res. 2011;189:113-36. doi: 10.1016/B978-0-444-53884-0.00021-X. PubMed 21489386 ↗
  • Williams C, Northstone K, Harrad RA, Sparrow JM, Harvey I; ALSPAC Study Team. Amblyopia treatment outcomes after screening before or at age 3 years: follow up from randomised trial. BMJ. 2002 Jun 29;324(7353):1549. doi: 10.1136/bmj.324.7353.1549. PubMed 12089090 ↗
  • Epelbaum M, Milleret C, Buisseret P, Dufier JL. The sensitive period for strabismic amblyopia in humans. Ophthalmology. 1993 Mar;100(3):323-7. doi: 10.1016/s0161-6420(13)32170-8. PubMed 8460000 ↗
  • Eibschitz-Tsimhoni M, Friedman T, Naor J, Eibschitz N, Friedman Z. Early screening for amblyogenic risk factors lowers the prevalence and severity of amblyopia. J AAPOS. 2000 Aug;4(4):194-9. doi: 10.1067/mpa.2000.105274. PubMed 10951293 ↗
  • Lions C, Bui-Quoc E, Bucci MP. Postural control in strabismic children versus non strabismic age-matched children. Graefes Arch Clin Exp Ophthalmol. 2013 Sep;251(9):2219-25. doi: 10.1007/s00417-013-2372-x. Epub 2013 May 9. PubMed 23657730 ↗
  • Scheiman MM, Hertle RW, Beck RW, Edwards AR, Birch E, Cotter SA, Crouch ER Jr, Cruz OA, Davitt BV, Donahue S, Holmes JM, Lyon DW, Repka MX, Sala NA, Silbert DI, Suh DW, Tamkins SM; Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol. 2005 Apr;123(4):437-47. doi: 10.1001/archopht.123.4.437. PubMed 15824215 ↗
  • Hertle RW, Scheiman MM, Beck RW, Chandler DL, Bacal DA, Birch E, Chu RH, Holmes JM, Klimek DL, Lee KA, Repka MX, Weakley DR Jr; Pediatric Eye Disease Investigator Group. Stability of visual acuity improvement following discontinuation of amblyopia treatment in children aged 7 to 12 years. Arch Ophthalmol. 2007 May;125(5):655-9. doi: 10.1001/archopht.125.5.655. PubMed 17502505 ↗
  • Lukman H, Kiat JE, Ganesan A, Chua WL, Khor KL, Choong YF. Negative social reaction to strabismus in school children ages 8-12 years. J AAPOS. 2011 Jun;15(3):238-40. doi: 10.1016/j.jaapos.2011.01.158. Epub 2011 Jun 16. PubMed 21683635 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03450980
Responsible party
Gang Luo, Ph.D. (Principal Investigator, Massachusetts Eye and Ear Infirmary) — Principal investigator
First posted
Mar 1, 2018
Start date
Feb 1, 2018
Primary completion
Dec 30, 2019
Completion
Jan 30, 2025
Results posted
Jul 14, 2025
Last update
Jul 14, 2025

Study contacts

Gang Luo, PhD
principal investigator · Massachusetts Eye and Ear

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion